| | Business Summary | | ArQule,
Inc.
seeks
to
bridge
the
gap
between
genomics
and
clinical
development
by
applying
its
proprietary
technology
platform
and
chemistry
capabilities
to
drug
discovery.
ArQule
offers
a
range
of
products
and
services
tailored
to
its
customers'
needs
for
drug
discovery
assistance.
The
Company's
products
and
programs
provide
solutions
for
the
lead
generation,
lead
qualification
and
lead
optimization
components
of
the
compound
discovery
process.
The
Company
focuses
on
making
the
compound
discovery
process
more
efficient,
less
expensive
and
more
likely
to
result
in
better
clinical
candidates.
ArQule's
products
include
Mapping
Array
Program,
Compass
Array
Program,
Directed
Array
Program
for
Lead
Optimization,
Target-Biased
Array,
Custom
Array
Program,
AMAP
Technology
Transfer,
Predictive
ADMET
Models
and
Integrated
Drug
Discovery
Platform. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | ArQule,
Inc.
offers
chemistry-based
products
and
services
that
improve
the
efficiency
and
effectiveness
of
the
drug
discovery
process.
For
the
six
months
ended
6/30/01,
revenues
increased
23%
to
$27.6
million.
Net
loss
totaled
$26.4
million,
up
from
$733
thousand.
Revenues
reflect
increased
delivery
of
compounds
to
Pfizer
Inc
and
Bayer
AG.
Higher
loss
reflects
a
$24.4
million
charge
related
to
the
merger
with
Camitro
Corporation. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Ariel Elia, 65
Chairman | -- | Stephen Hill, 41
Pres,
CEO | $469K | David Hastings, 39
CFO,
VP | -- | Philippe Bey, Ph.D., 58
Sr.
VP of Research and Devlepment and CSO | 398K | J. David Jacobs
VP,
Legal, Gen. Counsel | -- | | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/a/arql.gif)